Articles

Videos

Podcasts

Clinical

Novadoz Pharmaceuticals, who markets the product, has commenced shipping of the drug, available in bottles of 30 tablets.

FDA Approves Generic Tablets for Treatment of Gout

Febuxostat was FDA-approved in 2009 to treat gout in adults.

FDA Adds Boxed Warning for Febuxostat

The statement is intended to serve as a discussion guide for the risk factors, diagnosis, treatment and prevention of the disease.

Joint Clinical Consensus Statement Addresses Gout Treatment

Nonsteroidal anti-inflammatory drugs should be used as the first line treatment for acute gout.

New Clinical Consensus Statement Designed to Address Gout Treatment

The FDA has approved Duzallo (lesinurad and allopurinol; Ironwood Pharmaceuticals, Inc) for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone.

Clinical Pharmacology Update: Duzallo

Febuxostat (Uloric) could escalate heart-related and all-cause mortality.

FDA Warns Gout Drug May Increase Cardiovascular Death

Study finds high unmet need among patients with uncontrolled gout.

Gout Research to be Presented at American College of Rheumatology Meeting

The FDA has approved a new fixed-dose combination treatment for hyperuricemia in patients with uncontrolled gout.

FDA Approves Novel Fixed-Dose Combo Treatment for Gout

Duzallo (lesinurad and allopurinol) may result in better disease control among patients with gout.

Gout Drug Approved for Patients with Hyperuricemia

Lesinurad plus febuxostat provides dual mechanisms of action to lower urate levels for patients with tophaceous gout.